Skip to content
DraconiticResearch
Search Sources API
197,785 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY-NC-NDBlood neoplasia

Venetoclax plus hypomethylating agent improves response rates but not survival in TP53-mutated myelodysplastic syndromes.

  • Michael Canonico1
  • Parth Patel2
  • Najla H Al Ali3
  • Ashwin Kishtagari2,4
  • Kateryna Fedorov2,4
  • Hayley Hawkins2
  • Katherine Walsh2,4
  • Kathryn Kennedy4
  • Erica Mittlebeeler4
  • Sarah Profitt4
  • Callee M Brooks4
  • Laura A Lee4
6 more authors
  • Sanjay R Mohan2,4
  • Emily F Mason4
  • Rami S Komrokji3
  • Michael R Savona2,4,5
  • David A Sallman3
  • Somedeb Ball2,4
5 affiliations
  1. 1Department of Medicine, School of Medicine, Vanderbilt University, Nashville, TN.
  2. 2Division of Hematology and Oncology, Department of Medicine, School of Medicine, Vanderbilt University, Nashville, TN.
  3. 3Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.
  4. 4Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.
  5. 5Program in Cancer Biology, School of Medicine, Vanderbilt University, Nashville, TN.
Read full textPDFDOICite

Related

  1. The fraction of CD117/c-KIT-expressing erythroid precursors predicts ESA response in low-risk myelodysplastic syndromes.
    Raimbault A, Itzykson R, Willems L +9
    Cytometry. Part B, Clinical cytometryPeer-reviewedLicence not statedFull text16 citedGeneral biologyGeneral medicineHAL
  2. Prolonged treatment-free remission after venetoclax in combination with a hypomethylating agent in acute myeloid leukemia with inv(16).
    Morgan L Shannon, Jared Wallace, Amy Kuo +1
    Annals of hematologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCPMC
  3. Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Valérie Bardet, Wagner-Ballon O, Guy J +12
    HaematologicaPeer-reviewedLicence not statedFull text43 citedGeneral biologyGeneral medicineHAL
  4. PANoptosis in the pathogenesis of myelodysplastic syndromes
    Rohit Thalla, Jyoti Lamichhane, Cameron Lewis +2
    Molecular OncologyPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  5. Myelodysplastic Syndromes-Transformed Acute Myeloid Leukemia With Concurrent DEK::CAN Fusion Gene Positivity and WT1 Overexpression: A Case Report and Literature Review.
    Wanxiu Mao, Tengmin Zhou, Xi Xu +3
    Cancer reports (Hoboken, N.J.)Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{canonico2026venetoclax,
  title = {{Venetoclax plus hypomethylating agent improves response rates but not survival in TP53-mutated myelodysplastic syndromes.}},
  author = {Michael Canonico and Parth Patel and Najla H Al Ali and Ashwin Kishtagari and Kateryna Fedorov and Hayley Hawkins and Katherine Walsh and Kathryn Kennedy and Erica Mittlebeeler and Sarah Profitt and Callee M Brooks and Laura A Lee and Sanjay R Mohan and Emily F Mason and Rami S Komrokji and Michael R Savona and David A Sallman and Somedeb Ball},
  journal = {Blood neoplasia},
  year = {2026},
  month = sep,
  doi = {10.1016/j.bneo.2026.100316},
  url = {https://europepmc.org/article/MED/42904072},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Venetoclax plus hypomethylating agent improves response rates but not survival in TP53-mutated myelodysplastic syndromes.
AU  - Michael Canonico
AU  - Parth Patel
AU  - Najla H Al Ali
AU  - Ashwin Kishtagari
AU  - Kateryna Fedorov
AU  - Hayley Hawkins
AU  - Katherine Walsh
AU  - Kathryn Kennedy
AU  - Erica Mittlebeeler
AU  - Sarah Profitt
AU  - Callee M Brooks
AU  - Laura A Lee
AU  - Sanjay R Mohan
AU  - Emily F Mason
AU  - Rami S Komrokji
AU  - Michael R Savona
AU  - David A Sallman
AU  - Somedeb Ball
PY  - 2026
DA  - 2026/09/21
JO  - Blood neoplasia
DO  - 10.1016/j.bneo.2026.100316
UR  - https://europepmc.org/article/MED/42904072
SN  - 2950-3280
ER  -